JCO Global Oncology最新文献

{"title":"Confronting the Challenges of Hepatocellular Carcinoma in Sub-Saharan Africa: Opportunities for Progress.","authors":"Sulaiman Nanji, Peter Kingham, Olusegun Isaac Alatise","doi":"10.1200/GO-24-00645","DOIUrl":"https://doi.org/10.1200/GO-24-00645","url":null,"abstract":"","PeriodicalId":14806,"journal":{"name":"JCO Global Oncology","volume":"11 ","pages":"e2400645"},"PeriodicalIF":3.2,"publicationDate":"2025-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144180036","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Navigating Challenges in Palliative Care: A Survey on ASCO Guideline Adherence Among Health Care Providers in Low- and Middle-Income Countries.","authors":"Cristiane Decat Bergerot, Enrique Soto-Perez-de-Celis, Chadane Thompson, Rushil Patel, Jafar Al-Mondhiry, Tingting Zhang, Nathasha Dhawan, Darcy Burbage, Joseph McCollom, Mazie Tsang, Ramy Sedhom, William E Rosa","doi":"10.1200/GO-24-00625","DOIUrl":"10.1200/GO-24-00625","url":null,"abstract":"<p><strong>Purpose: </strong>Integrating palliative care into oncology is essential, yet disparities in access and quality persist, particularly in low- and middle-income countries (LMICs). The ASCO guidelines advocate for early, routine, interdisciplinary palliative care for patients with advanced cancer. Barriers to implementing these recommendations include resource limitations, inadequate training, and cultural perceptions. Recognizing these challenges is essential for improving equitable access to palliative care worldwide.</p><p><strong>Methods: </strong>This prospective survey assessed adherence to ASCO recommendations for palliative care integration among LMIC health care providers (HCPs). Participants were recruited via e-mail, social media, and a list of members involved in the ASCO Palliative Care Communities of Practice from February to May 2024. The survey included sections on sociodemographic information, self-perceived adherence to ASCO guidelines on a 5-point Likert scale, and open-ended questions on implementation barriers. Data were collected using Research Electronic Data Capture system. Participants were grouped by WHO regions. Descriptive statistics were used to summarize characteristics and adherence scores, and chi-square tests were used to evaluate regional differences. Thematic analysis identified key themes from open-ended responses.</p><p><strong>Results: </strong>One hundred eighty HCPs participated; 62% was female, and 51.1% was age 35-44 years. Most were physicians (66%), and 50% lacked palliative care specialization. Adherence to ASCO guidelines varied, with early palliative care referrals ranging from 50% in the Americas region to 0% in the Western Pacific region. Key barriers included lack of policy support (25%), unmet educational needs (22%), and accessibility constraints (19%).</p><p><strong>Conclusion: </strong>Addressing identified barriers through evidence-based advocacy, comprehensive policy changes, training, and continuing education programs is essential for integrating palliative care into oncology services across LMICs, promoting health equity for patients with cancer.</p>","PeriodicalId":14806,"journal":{"name":"JCO Global Oncology","volume":"11 ","pages":"e2400625"},"PeriodicalIF":3.2,"publicationDate":"2025-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12123599/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144127624","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Development and Validation of an Adapted Tool to Measure Health-Related Social Needs for the Prostate Cancer Population in Nigeria.","authors":"Musliu Adetola Tolani, Mudi Awaisu, Christian Agbo Agbo, Ayodeji Olawale Afolayan, Kabir Abdulkareem, Bernice Ofori, Sarah Sandlow, Dennis Li, Adam Murphy","doi":"10.1200/GO-24-00525","DOIUrl":"https://doi.org/10.1200/GO-24-00525","url":null,"abstract":"<p><strong>Purpose: </strong>The lack of culturally appropriate tools is a key obstacle to the identification of unmet social needs in the cancer population of Nigeria. To support sustainable strategies for social needs screening and intervention, this study aimed to develop and validate a health-related social needs screening tool for the prostate cancer population in Nigeria.</p><p><strong>Patients and methods: </strong>The study was performed in three stages at three Nigerian tertiary hospitals: (1) instrument adaptation using the Health Leads social needs screening toolkit as the primary framework, which involved domain specification and question item prioritization through three rounds of Delphi surveys among 15 health care workers, 15 patients with prostate cancer, and 15 caregivers; (2) face validation among 10 patients with prostate cancer through cognitive interviews for feedback on format, language clarity, ease of answering, comprehensiveness and applicability, and then member checking to review and approve question modifications; and (3) pilot testing for reliability analysis and readability assessment among 30 patients with prostate cancer. Descriptive and inferential statistics and qualitative analysis were performed.</p><p><strong>Results: </strong>During the first Delphi round, the highest three of the 10 top-ranking domains were financial resource strain (84%), sociodemographics (80%), and behavioral/mental health (80%). For single-question item prioritization, an agreement was reached in the employment, education, social isolation, and supports domains during the second round, and for the remaining domains during the third round. The format, clarity, ease of answering, and comprehensiveness of seven question items were modified, and two question items were substituted during face validation. The modified tool had a Cronbach's α of .67 and was considered appropriate for second-grade readers.</p><p><strong>Conclusion: </strong>To our knowledge, this study developed the first screening tool with acceptable internal validity and understandability to assess social needs in the prostate cancer population of Nigeria.</p>","PeriodicalId":14806,"journal":{"name":"JCO Global Oncology","volume":"11 ","pages":"e2400525"},"PeriodicalIF":3.2,"publicationDate":"2025-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144127613","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Projected Prostate Cancer Incidence in the Middle East by 2050: Socioeconomic Disparities and Future Implications.","authors":"James Parisi, Yetkin Tuac, Okan Argun, Garrett Kearney, Luke W Chen, Ozlem Aynaci, Nadeem Pervez, Layth Mula-Hussain, Jonathan E Leeman, Miranda B Lam, Mutlay Sayan","doi":"10.1200/GO-25-00098","DOIUrl":"https://doi.org/10.1200/GO-25-00098","url":null,"abstract":"<p><strong>Purpose: </strong>Prostate cancer poses a significant public health challenge in the Middle East, with advanced-stage diagnoses and high mortality rates. However, projections regarding its future incidence are limited. The aims of this study were to estimate prostate cancer incidence in the region through 2050, to evaluate socioeconomic factors contributing to regional disparities, and to provide insights to inform future health care policies and resource allocation.</p><p><strong>Methods: </strong>Data from the Global Cancer Observatory were analyzed for Middle Eastern countries, with Europe and North America included for comparison. The percentage change in incidence between 2022 and 2050 was compared across regions using the Mann-Whitney <i>U</i> test. Additional subgroup analyses based on income level and Human Development Index were performed using Kruskal-Wallis test. Spearman rank correlation was used to explore the association between incidence trends and socioeconomic indicators.</p><p><strong>Results: </strong>In 2022, Middle Eastern countries reported 50,944 patients with newly diagnosed prostate cancer, accounting for 3.47% of global incidence. The projected increase in prostate cancer incidence by 2050 was significantly higher in the Middle East compared with Europe and North America (mean rank, 12.50 <i>v</i> 1.50; <i>P</i> = .009). Higher income countries exhibited a greater percentage increase (<i>P</i> = .033), and the income level correlated positively with incidence trends (<i>r</i> = 59.6%; <i>P</i> = .006). Countries with increasing incidence rates had a markedly higher percentage change than those expected to decline (<i>P</i> = .031).</p><p><strong>Conclusion: </strong>Prostate cancer incidence in the Middle East is expected to rise substantially by 2050, with socioeconomic disparities influencing disease trends. These findings highlight the urgent need for targeted awareness campaigns, improved screening strategies, enhanced oncology infrastructure, and strengthened cancer registries to mitigate the projected burden and improve outcomes in the region.</p>","PeriodicalId":14806,"journal":{"name":"JCO Global Oncology","volume":"11 ","pages":"e2500098"},"PeriodicalIF":3.2,"publicationDate":"2025-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144181831","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Outcomes of Adolescent and Young Adult Women With Breast Cancer in Rural and Urban Saskatchewan: A Retrospective Cohort Study.","authors":"Erika Arnold, Devin Laubscher, Huzaifa Saeed, Osama Ahmed, Ayesha Bashir, Haji Chalchal, Gary Groot, Duc Le, Mita Manna, Pamela Meiers, Prosanta Mondal, Shahid Ahmed","doi":"10.1200/GO-25-00018","DOIUrl":"https://doi.org/10.1200/GO-25-00018","url":null,"abstract":"<p><strong>Purpose: </strong>Breast cancer is uncommon in adolescent and young adult (AYA) women, accounting for approximately 1.8% of all breast cancers. There is a risk of delayed diagnosis of breast cancer among AYA women, especially among those residing in rural areas. The aim of this study was to assess the outcomes of AYA women for breast cancer in relation to rural residence.</p><p><strong>Methods: </strong>This cohort study evaluated all women aged 35 years and younger with histologically confirmed breast cancer diagnosed between 2000 and 2019 in a Canadian province. A multivariate Cox proportional hazards model was used to assess the prognostic significance of rural residence and other variables for overall survival (OS) across all stages and disease-free survival in early-stage breast cancer.</p><p><strong>Results: </strong>A total of 248 eligible AYA women with a median age of 32 years were identified, of whom 24% were younger than 30 years. Of all patients, 51% had node-positive disease, and 11% had stage IV disease at diagnosis. Among those with invasive breast cancer, 45% had hormone receptor-positive and human epidermal growth factor receptor 2 (HER2)-negative disease; 30% had HER2-positive disease; and 25% had triple-negative breast cancer (TNBC). There were 53% rural and 47% urban residents. In multivariate analysis for OS for stage 0 to IV disease, rural residence (hazard ratio [HR], 1.75 [95% CI, 1.08 to 2.81]), TNBC (HR, 2.25 [95% CI, 1.34 to 3.80]), and stage IV disease (HR, 8.1 [95% CI, 4.72 to 13.94]) were associated with inferior OS.</p><p><strong>Conclusion: </strong>AYA women with breast cancer have a high incidence of node-positive disease and aggressive subtypes. This study found a significant association between rural residence and OS. These findings emphasize the need for enhanced early detection and personalized treatment strategies, particularly for rural patients and those with TNBC.</p>","PeriodicalId":14806,"journal":{"name":"JCO Global Oncology","volume":"11 ","pages":"e2500018"},"PeriodicalIF":3.2,"publicationDate":"2025-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144005812","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Cause-Specific Mortality in a Cohort of 1,435 Patients With Hodgkin Lymphoma Treated Between 1985 and 2014: A Nationwide Chilean Cohort Study.","authors":"Maria Elena Cabrera, Monica Civallero, Yana Stepanishyna, Lea Derio, Tetiana Skrypets, Vivianne Lois, Valeska Vega, Susana Calderon, Hernán Rojas, Alvaro Pizarro, M Gabriela Mendoza, Monica Romero, Christine Rojas, Jacqueline Oliva, Marvila Intriago, Bernardita Rojas, Luana Conte, Luigi Marcheselli, Massimo Federico","doi":"10.1200/GO-24-00344","DOIUrl":"https://doi.org/10.1200/GO-24-00344","url":null,"abstract":"<p><strong>Purpose: </strong>Hodgkin lymphoma (HL) is classified as the first malignancy to be cured by a combination of chemotherapy and radiotherapy. However, the life expectancy of HL survivors is hampered by the occurrence of late adverse events, including second malignant neoplasms (SMNs) and cardiovascular diseases (CVDs).</p><p><strong>Patients and methods: </strong>We investigated the causes of death in a cohort of 1,435 patients over age 15 years treated at 18 different public cancer centers in Chile.</p><p><strong>Results: </strong>After a median follow-up of 19 years (0-37), the 5-year overall survival improved from 64% in the cohort 1985-1994 to 81% in the cohort 2009-2014 (<i>P</i> < .001). HL was the main cause of death in the first 10 years after treatment, whereas SMN and CVD risk peaked 10-15 years and remained raised for 30 years or longer. Cumulative incidence of deaths (CIDs) due to SMNs resulted significantly higher in patients treated with cyclophosphamide, vincristine, procarbazine, prednisone (MOPP)/MOPP-like regimens over doxorubicin, bleomycin, vinblastine, dacarbazine. CIDs due to CVDs increased from 0.4 to 4.1 at 5 and 20 years, respectively.</p><p><strong>Conclusion: </strong>HL survivors continue to have a reduced life expectancy due to an increased risk of dying of SMNs and/or CVDs, although it was lower among patients treated in the most recent calendar period studied (2002-2014).</p>","PeriodicalId":14806,"journal":{"name":"JCO Global Oncology","volume":"11 ","pages":"e2400344"},"PeriodicalIF":3.2,"publicationDate":"2025-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143997323","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Mapping the Distribution and Challenges of Long-Distance Travel for Patients With Breast Cancer at the Uganda Cancer Institute.","authors":"Naghib Bogere, Bridget Sharon Angucia, Eva Kababiito Nangobi, Joanne Kayaga, Margaret Okello Nyeko, Margaret Nanteza Okello, Edinus Mable Namusoke, Joanita Kuratex Mirembe, Immaculate Mbarusha, Ezra Anecho, Benjamin Mwesige, Nixon Niyonzima, Victoria Abaliwano Walusansa","doi":"10.1200/GO-24-00533","DOIUrl":"https://doi.org/10.1200/GO-24-00533","url":null,"abstract":"<p><strong>Purpose: </strong>Breast cancer is a major public health concern in Uganda, with limited research on its spatial distribution. With the increasing burden of breast cancer in Uganda, ensuring equitable access to care is crucial. This study investigates the spatial distribution of breast cancer cases across Uganda and describes travel distances patients travel to reach the Uganda Cancer Institute (UCI), the national cancer treatment center. By analyzing geographic patterns and disparities in accessibility, this research aims to inform targeted interventions for improved patient outcomes and a more equitable health care system.</p><p><strong>Patients and methods: </strong>This retrospective study analyzed data from patients with breast cancer treated at UCI from 2009 to 2023. We geocoded patient addresses and calculated the travel distance from each residence to UCI. Spatial analysis was performed using Moran I statistic to assess clustering patterns in breast cancer distribution.</p><p><strong>Results: </strong>This study mapped the residences of 1,926 patients with breast cancer. Over half (54.7%) were concentrated in the Central region, with a median distance to the UCI of 11.2 km. By contrast, patients from the Northern region faced a median journey of 291 km, highlighting a significant disparity in proximity to care. Distinct clusters of patients were identified beyond the capital, Kampala, notably in Mbale (Eastern region) and several towns within the Northern region (Arua, Adjumani, Gulu, and Lira), suggesting potential localized factors influencing breast cancer incidence.</p><p><strong>Conclusion: </strong>This study highlights significant regional disparities in access to breast cancer care in Uganda, emphasizing the need for targeted interventions to improve health care access and reduce the burden of long-distance travel for patients in remote areas.</p>","PeriodicalId":14806,"journal":{"name":"JCO Global Oncology","volume":"11 ","pages":"e2400533"},"PeriodicalIF":3.2,"publicationDate":"2025-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144016262","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Triple Oral Metronomic Chemotherapy Versus Chemotherapy of Physician Discretion After Failure of Platinum-Based Therapy in Advanced Head and Neck Cancer: A Phase III Randomized Study (METRO-CHASE Study).","authors":"Akhil Kapoor, Anuj Gupta, Bipinesh Sansar, Bal Krishna Mishra, Pooja Gupta, Arpita Singh, Arvind Upadhyay, Lakhan Kashyap, Ankita Pal, Amit Kumar, Sambit S Nanda, Ashutosh Mukherji, Ankita Rungta Kapoor, Satyajit Pradhan, Aseem Mishra, Zachariah Chowdhury, Shashikant Patne, Ipsita Dhal, Neha Singh, Shreya Shukla, Satyendra Narayan Singh, Varun Shukla, M V Manikandan, Arvind Suresh, Shripad Banavali, Somnath Dey, Kunal Ranjan Vinayak, Praveen Lakshman, Lokendra Gupta, Pratibha Gavel, Bhavesh P Bandekar, Vijay Patil, Vanita Noronha, Kumar Prabhash","doi":"10.1200/GO-25-00032","DOIUrl":"https://doi.org/10.1200/GO-25-00032","url":null,"abstract":"<p><strong>Purpose: </strong>Platinum-refractory advanced head and neck squamous cell carcinoma (HNSCC) has poor outcomes and limited treatment options, especially in resource-constrained settings. Triple oral metronomic chemotherapy (OMCT), involving low-dose continuous administration of chemotherapeutic agents, has shown promise in phase II studies but lacks evidence from randomized controlled trials. This study evaluated whether triple OMCT improves overall survival (OS) compared with chemotherapy of physician discretion (CPD).</p><p><strong>Patients and methods: </strong>In this phase III randomized open-label study, 214 patients with advanced HNSCC who had previous platinum-based chemotherapy were randomly assigned 1:1 to receive either triple OMCT (arm A) with erlotinib, celecoxib, and methotrexate, or CPD (arm B). The primary end point was OS, with secondary end points including progression-free survival (PFS), quality of life (QOL), and safety. Kaplan-Meier and log-rank tests were used for OS and PFS, and Cox-proportional hazard models estimated hazard ratios. QOL was evaluated using European Organisation for Research and Treatment of Cancer QLQ-C30 and FACT H&N.</p><p><strong>Results: </strong>Median OS was 5 months in arm A and 3.1 months in arm B (hazard ratio [HR], 0.63 [95% CI, 0.47 to 0.83]; <i>P</i> = .00011). Median PFS was 4.8 months in arm A and 2.7 months in arm B (HR, 0.67 [95% CI, 0.52 to 0.87]; <i>P</i> < .0001). Previous treatment was a significant prognostic factor for OS, while age, tumor site, and previous treatment were significant for PFS. Triple OMCT improved global health status, physical functions, fatigue, and insomnia. It was well tolerated, with fewer grade 3 or higher adverse events than CPD (28.0% <i>v</i> 39.3%, <i>P</i> = .03).</p><p><strong>Conclusion: </strong>Triple OMCT is an effective and safe treatment for advanced HNSCC after platinum-based chemotherapy.</p>","PeriodicalId":14806,"journal":{"name":"JCO Global Oncology","volume":"11 ","pages":"e2500032"},"PeriodicalIF":3.2,"publicationDate":"2025-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144127631","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Temporal Evolution in Patient-Reported Outcomes in Indian Women With Breast Cancer: A Longitudinal Study.","authors":"Suman Ghosh, Tabassum Wadasadawala, Sanjay Mohanty, Rajiv Sarin, Vani Parmar, Sudeep Gupta","doi":"10.1200/GO-24-00507","DOIUrl":"https://doi.org/10.1200/GO-24-00507","url":null,"abstract":"<p><strong>Purpose: </strong>Breast cancer (BC) is the most common malignancy among women in India and globally. Given the high survivorship, understanding the evolution of health-related quality of life (HRQoL) is crucial, yet comprehensive longitudinal studies from India are lacking.</p><p><strong>Patients and methods: </strong>This prospective observational study included 500 patients with BC registered between June 2019 and March 2022. HRQoL was assessed at pretreatment, treatment completion, and 6-month follow-up using European Organisation for Research and Treatment of Cancer (EORTC)-QLQ-C30, EORTC-QLQ-BR-23, and EQ-5D-5L tools. A linear mixed-effects model analyzed HRQoL trajectories and predictors.</p><p><strong>Results: </strong>The median patient age was 46 years, with 60.8% presenting with locally advanced disease; all patients underwent multimodal therapy, comprising surgery (57% mastectomy), chemotherapy (95%), and radiotherapy (RT; 77%). Pretreatment global QoL scores were influenced by age (younger fared better, <i>P</i> = .003), stage (<i>P</i> = .027), and social displacement (<i>P</i> = .038). Longitudinal assessment revealed a small decline in global QoL (-2.1) and EQ-VAS (-1.9), along with meaningful improvements in social (+12.8), cognitive (+4.3), and role function (+7.3). Symptom burden significantly decreased, except for deterioration in body image (-7) and sexual enjoyment (-16). Younger patients had slower recovery in physical (<i>P</i> = .003) and social function (<i>P</i> = .05), while school education and financial independence positively influenced QoL variation. Social displacement affected trajectories of QoL (<i>P</i> = .017), role (<i>P</i> = .032), and social function (<i>P</i> = .024). Extent of surgery and RT did not affect overall HRQoL trends, although RT recipients reported more fatigue (<i>P</i> = .029).</p><p><strong>Conclusion: </strong>To our knowledge, this is the first longitudinal HRQoL study in Indian patients with BC, showing significant improvement in most functional domains at early survivorship. Sociodemographic factors, such as age, social displacement, education, and financial independence, rather than treatment modalities, were stronger predictors of HRQoL. Longer follow-up is needed for a more comprehensive assessment.</p>","PeriodicalId":14806,"journal":{"name":"JCO Global Oncology","volume":"11 ","pages":"e2400507"},"PeriodicalIF":3.2,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144025901","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Impact of Comorbidities on Patients With Waldenström Macroglobulinemia in Taiwan: A Multicenter Study.","authors":"Yu-Sung Chang, Yu-Hsuan Tuan, Jun-Wei Gao, Chao-Hung Wei, Po-Ju Chiu, Ta-Chuan Yu, Tai-Chung Huang","doi":"10.1200/GO-24-00576","DOIUrl":"https://doi.org/10.1200/GO-24-00576","url":null,"abstract":"<p><strong>Purpose: </strong>Comorbidities adversely affect the prognosis of several low-grade B-cell lymphomas, yet their influence in Waldenström macroglobulinemia (WM) remains unexplored. This study aimed to comprehensively evaluate the clinical characteristics, treatment landscape, and survival outcomes in patients with WM, with a specific focus on the prognostic significance of comorbidities in an Asian cohort.</p><p><strong>Materials and methods: </strong>This retrospective analysis included patients with WM from September 2002 to September 2023 using the Integrative Medical Data Center of National Taiwan University Hospital database. The primary end points were survival data stratified by prognostic factors.</p><p><strong>Results: </strong>A total of 135 patients with WM were included, with a median age of 66.8 years. Sixty-eight percent had at least one comorbidity, with a median Charlson comorbidity index score of 5.5. The median overall survival (OS) was 9.2 years. Multivariable analysis revealed that high-risk International Prognostic Scoring System for Waldenström macroglobulinemia (IPSSWM; hazard ratio [HR], 3.84 [95% CI, 1.14 to 13.0]; <i>P</i> = .03) was significantly associated with a poor OS, while cytogenetic abnormalities (HR, 2.10 [95% CI, 0.92 to 4.82]; <i>P</i> = .08) and a high comorbidity burden (HR, 1.90 [95% CI, 0.96 to 3.74]; <i>P</i> = .065) demonstrated a notable trend toward worse outcomes. Among patients without anti-hepatitis B virus (HBV) prophylaxis, 100% of the HBV carriers experienced reactivation, compared with 17.5% of those with remote HBV infections.</p><p><strong>Conclusion: </strong>Real-world WM data were used to validate the prognostic value of IPSSWM and revised IPSSWM in an Asian population. High comorbidity burden was associated with a poor survival, and the need for HBV prophylaxis was disclosed in patients with a history of HBV infection.</p>","PeriodicalId":14806,"journal":{"name":"JCO Global Oncology","volume":"11 ","pages":"e2400576"},"PeriodicalIF":3.2,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143965497","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}